Is Haemonetics Corp. overvalued or undervalued?

As of 17 October 2025, Haemonetics Corp. has moved from a fair to a very attractive valuation grade. The company is currently undervalued, supported by a P/E ratio of 22, an EV to EBITDA of 13.04, and a PEG ratio of 8.36. In comparison, its peers show more favorable valuations, with Haemonetics' P/E ratio significantly lower than Masimo Corp. at 179.74 and Bio-Rad Laboratories, Inc. at 16.20.
Despite its attractive valuation, Haemonetics has underperformed against the S&P 500, with a year-to-date return of -35.63% compared to the index's gain of 13.30%. This stark contrast in performance highlights the potential for recovery and value realization in Haemonetics Corp.